Treatment Patterns and FLT3 Mutation Testing Among Patients with Acute Myeloid Leukemia in China: A Retrospective Observational Study
Li-Jen Cheng,Benfa Gong,Christopher Young,Prabhuram Krishnan,Ying Wang,Hui Wei,Chunlin Zhou,Shuning Wei,Yan Li,Qiuyun Fang,Jia Zhong,Eric Wu,Yingchang Mi,Jianxiang Wang
DOI: https://doi.org/10.2147/tcrm.s434556
2024-02-13
Therapeutics and Clinical Risk Management
Abstract:Benfa Gong, 1 Li-Jen Cheng, 2 Christopher H Young, 3 Prabhuram Krishnan, 2 Ying Wang, 1 Hui Wei, 1 Chunlin Zhou, 1 Shuning Wei, 1 Yan Li, 1 Qiuyun Fang, 1 Jia Zhong, 4 Eric Q Wu, 5 Yingchang Mi, 1 Jianxiang Wang 1 1 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China; 2 Medical Affairs, Astellas Pharma Singapore Pte. Ltd., Singapore; 3 Advanced Informatics & Analytics, Astellas Pharma US Inc., Northbrook, IL, USA; 4 Analysis Group, Inc., Beijing, People's Republic of China; 5 Analysis Group, Inc., Boston, MA, USA Correspondence: Jianxiang Wang, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, People's Republic of China, Tel +86 13821389157, Email Introduction: For acute myeloid leukemia (AML), prognosis is particularly poor in patients harboring FMS-like tyrosine kinase 3 ( FLT3 ) gene mutations, though routine screening for these mutations at diagnosis has been shown to be insufficient. The understanding of the impact of FLT3 mutations on treatment decisions is limited. Methods: In this retrospective, observational study, we investigated the key epidemiological characteristics, treatment patterns and responses among adult patients with newly diagnosed (ND) AML in China, who initiated treatment from January 1, 2015, to December 31, 2019, or progressed to relapsed/refractory (R/R) AML by December 31, 2020. Results: Of the 853 ND AML patients included, 63.4% were screened for FLT3 status, and 20.1% tested positive ( FLT3 MUT ) at initial diagnosis. Of 289 patients who progressed to R/R AML during the study period, 24.9% were screened at the diagnosis of R/R AML, and 19.4% tested positive; 20.5% of screened patients changed FLT3 status at first diagnosis of R/R AML. Initial treatment regimens or treatment responses did not seem to differ in patients with ND AML by FLT3 mutation status. In patients with R/R AML, there was an apparent difference in second-line treatment choices by FLT3 mutation status; however, the number of FLT3 -mutated patients were limited to demonstrate any meaningful distinction. FLT3 -mutated R/R AML was associated with shorter relapse time. Conclusion: Study findings showed that there was a lack of routine testing for FLT3 mutations at first diagnosis of R/R AML, and initial treatment decisions did not differ by FLT3 mutation status. Given the clinical burden of FLT3 MUT , likelihood of FLT3 status changes, and emerging FLT3 inhibitors, further routine FLT3 screening is needed to optimize treatment of R/R AML. Keywords: acute myeloid leukemia, epidemiology, real-world, retrospective study Graphical Acute myeloid leukemia (AML) is the predominant form of leukemia in adults, both globally and in China. 1–3 It is characterized by the rapid proliferation of undifferentiated myeloblasts and a poor prognosis, particularly for older individuals, with most patients relapsing after initial treatment. 4,5 For patients with newly diagnosed (ND) AML, initial treatment comprises induction chemotherapy to reduce leukemic cell numbers to below detectable levels, followed by consolidation therapy to eliminate any remaining leukemic cells and reduce the risk of relapse. 6,7 Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) is indicated for use either as first-line therapy in patients achieving remission following chemotherapy, for whom the estimated probability of relapse without allo-HSCT would be >35–40%, or as second-line treatment following relapse after initial chemotherapy. 8 However, relapse after allo-HSCT is relatively common (25–55%), with survival rates after 4 years ranging between 20% and 35%. 9 As an alternative therapeutic pathway, several key genetic mutations have been shown to be closely associated with the pathogenesis of AML and poorer prognoses in AML patients, 10,11 with their inhibition linked to improved clinical outcomes in relapsed/refractory (R/R) AML patients. 12 Recent advances in next-generation sequencing technology have enhanced our understanding of these mutations underlying AML and the genomic heterogeneity between patients, 5 providing an opport -Abstract Truncated-
health care sciences & services